Press Releases

Press Releases
Date Title and Summary View
Nov 2, 2007 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 2, 2007--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on seeking to develop proprietary targeted medicines primarily for cancer treatment, today announced that the Company will be presenting at the CIBC World Markets 18th Annual Healthcare Conference, which is being held on November ...
Oct 31, 2007 CAMBRIDGE, Mass., Oct 31, 2007 (BUSINESS WIRE) -- Curis, Inc. (NASDAQ: CRIS), a drug development company focused on seeking to develop proprietary targeted medicines primarily for cancer treatment, today announced that the Company will be presenting at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference, which is being he...
Oct 30, 2007 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 30, 2007--Curis, Inc. (NASDAQ:CRIS), a drug development company focused on seeking to develop novel targeted medicines primarily for cancer treatment, today reported its financial results for the third quarter ended September 30, 2007. For the third quarter of 2007, we reported a net loss o...
Oct 25, 2007 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 25, 2007--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on seeking to develop proprietary targeted medicines primarily for cancer treatment, today announced a presentation at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, which is being ...
Oct 23, 2007 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 23, 2007--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on seeking to develop novel targeted medicines primarily for cancer treatment, will release its third quarter financial results on Tuesday, October 30, 2007 before the market opens. The Company will also hold a conference call on...
Oct 17, 2007 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 17, 2007--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on seeking to develop proprietary targeted medicines primarily for cancer treatment, today announced a presentation at CHI's Discovery on Target: Developing Inhibitors for Promising Drug Targets, which is being held at the World ...
Oct 16, 2007 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 16, 2007--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on seeking to develop proprietary targeted medicines primarily for cancer treatment, today announced that Genentech has initiated an expansion cohort in its ongoing Phase I clinical trial of a systemically administered Hedgehog a...
Oct 3, 2007 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 3, 2007--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on seeking to develop novel targeted medicines primarily for cancer treatment, today announced that the company will be presenting at BIO InvestorForum 2007, which is being held from October 9-11, 2007 at the Palace Hotel in San F...
Sep 25, 2007 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sept. 25, 2007--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on seeking to develop proprietary targeted medicines primarily for cancer treatment, today provided an update on CUDC-101 and other preclinical drug candidates under its Targeted Cancer Drug Development Platform. The Company is ...
Aug 28, 2007 CAMBRIDGE, Mass., Aug 28, 2007 (BUSINESS WIRE) -- Curis, Inc. (NASDAQ: CRIS), a drug development company focused on seeking to develop novel targeted medicines primarily for cancer treatment, today announced that it was notified by one of its corporate partners, Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), that preliminary data wi...
FirstPrevious ...
34
NextLast
Add to Briefcase = add release to Briefcase